Bio Medica Laboratories IPO
Bio Medica Laboratories IPO Listing Day Performance
Bio Medica Laboratories listed on NSE SME on 29 May 2026 at ₹111.20, a 20% discount to the issue price of ₹139. A retail investor allotted the minimum application of 2,000 shares (2 lots) lost ₹55,600 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹-6 (-4.3%) |
| GMP-implied listing | ₹133 |
| Actual listing | ₹111.20 |
| Difference | −₹21.8 (−16.4%) |
Demand going into listing
| Subscribed overall | 2.31× |
| QIB | 15.94× |
| NII | 1.41× |
| Retail | 2.92× |
Market Sentiment
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Day 3 | Day 5 |
|---|---|---|---|---|
| QIB | 15.94x | 15.94x | 15.94x | 15.94x |
| NII | 0.03x | 0.38x | 0.38x | 1.41x |
| bNII > ₹10L | 0.01x | 0.35x | 0.35x | 1.02x |
| sNII 2-10L | 0.06x | 0.46x | 0.46x | 2.19x |
| Retail | 1.09x | 1.42x | 1.42x | 2.92x |
| Total | 0.68x | 1.00x | 1.00x | 2.31x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2023 | 2024 | 2025 | Nov 2025 |
|---|---|---|---|---|
| Revenue | 16.25 | 15.34 | 38.33 | 28.63 |
| Expense | 15.80 | 11.69 | 25.18 | 16.95 |
| Profit (PAT) | 0.33 | 2.50 | 9.79 | 8.66 |
| Total Assets | 17.57 | 19.53 | 39.12 | 65.17 |
Peer Comparison
| Company | EPS | P/E |
|---|---|---|
| Zenotech Laboratories Limited | 0.92 | - |
| Shukra Pharmaceuticals Limited | 0.22 | 47.57 |
Promoters & Holding Pattern
Promoters: Mr. Mukesh Mehta and Mr. Pradeep Mehta
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 91,80,001 | 99.99% |
Strengths & Risks
- Strong institutional (QIB) demand — 15.9x.
- Revenue grew 150% in the latest reported year.
- Solid profit margin — 25.5%.
- Strong return on equity — 100%.
- Mostly fresh capital — proceeds fund the company's growth, not an exit.
- Elevated leverage — debt/equity of 1.02.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Bio Medica Laboratories at a glance
From the company's description: “Bio Medica Laboratories is one of the leading manufacturers of parenteral medicines (injectable products) in India.”
Bio Medica Laboratories is raising ₹52.43 crore through an IPO on the NSE Emerge (SME). Of that, ₹47.19 crore is a fresh issue — new shares, with the money going to the company — and ₹5.24 crore is an offer for sale by existing shareholders, who keep those proceeds; 90% of the issue therefore reaches the business. Main stated uses of the fresh money: Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (₹24.81 crore) and Repayment of Loan (₹7.25 crore).
Revenue went from ₹16.25 crore in 2023 to ₹38.33 crore in 2025, up 136% over 2 years. Profit after tax went from ₹0.33 crore to ₹9.79 crore, a net margin of 26% in the latest year. The path was not a straight line: revenue dipped in between before recovering.
Debt stands at 1.02 times equity.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Bio Medica Laboratories Ltd., Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore),, Indore, Madhya Pradesh, 452015
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Repayment of Loan | 7.25 |
| Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | 24.81 |
| General Corporate Purpose | - |
Resources & Documents
Bio Medica Laboratories IPO - Quick Take
Bio Medica Laboratories has set a price band of Rs 132–Rs 139 per share for an issue size of Rs 52 crore. The stock listed with a 20.00% discount versus its issue price on May 29, 2026.
The issue is promoted by Mr. Mukesh Mehta and Mr. Pradeep Mehta with Narnolia Financial Services Ltd. acting as lead manager. Net proceeds will primarily be used towards repayment of Loan (Rs 7 crore) and enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (Rs 25 crore).
On fundamentals, the company is posting revenue growth of 149.9%, a profit margin of 25.5%, return on equity of 99.6% in its most recent reported period. Listed peers in this segment include Shukra Pharmaceuticals Limited (P/E 47.57x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read weak — several key indicators are reading below average. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Bio Medica Laboratories IPO: Lead Manager & Registrar Track Record
How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Bio Medica Laboratories itself, so they describe what came before it.
- Bio Medica Laboratories listed at −20% on day one; the median of 193 listings was +1.7% (better than 3% of them).
- Subscribed 2.31x against a median of 4.03x across 192 issues (higher than 39%).
- Average listing-day move across all 194 SME listings we track: +11.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| Narnolia Financial Services Ltd. Lead manager | 1 0 MB · 1 SME | 100% 1 of 1 | +6.9% | +6.9% |
| Skyline Financial Services Pvt.Ltd. Registrar | 16 0 MB · 16 SME | 75% 12 of 16 | Check allotment → | |
Recent listings managed by Narnolia Financial Services Ltd. (1)
| IPO | Listed | Listing-day move |
|---|---|---|
| Fusion Klassroom | 07 Aug 2026 | +6.9% |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Bio Medica Laboratories IPO GMP — What It Means
Its last GMP before listing was -4.3%. Of the 18 IPOs we have tracked with a final GMP below zero, 2 listed above, 0 flat and 16 below the issue price; Bio Medica Laboratories listed 20% below its issue price.
See the full Bio Medica Laboratories GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Bio Medica LaboratoriesNo comments yet. Be the first to share your opinion!